In terms of valuation, BioCryst Pharmaceuticals Inc’s market capitalization stands at $1.66 billion. Market cap represents the total value of all outstanding shares and is a key indicator of a company ...

Hidden gems in the biotech sector are reshaping healthcare with breakthroughs in personalized medicine and rare disease ...

BioCryst Pharmaceuticals Inc (BCRX) stock saw a modest uptick, ending the day at $7.73 which represents a slight increase of $0.11 or 1.44% from the prior close of $7.62. The stock opened at $7.58 and ...

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Get Free Report) has been given an average recommendation of “Moderate Buy” by ...

RBC Capital analyst Brian Abrahams maintained a Buy rating on BioCryst (BCRX – Research Report) on January 21 and set a price target of $10.00.

64.4% of Immatics shares are held by institutional investors. Comparatively, 85.9% of BioCryst Pharmaceuticals shares are held by institutional investors. 3.3% of Immatics shares are held by ...

BioCryst (NASDAQ:BCRX) released its preliminary 2024 revenue results, along with guidance for 2025.The company said it expects to report 2024 net revenue of $450M, up 36% from the prior year, with ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

RBC Capital analyst Brian Abrahams maintained a Buy rating on BioCryst (BCRX – Research Report) on January 7 and set a price target of $10.00. The company’s shares closed last Wednesday at $8.05.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...